LitAlert ~~ GeneLit.com

    • Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    • Iyevleva AG, Aleksakhina SN, Sokolenko AP, Baskina SV, Venina AR, Anisimova EI, Bizin IV, Ivantsov AO, Belysheva YV, Chernyakova AP, Togo AV, Imyanitov EN.
    • Breast Cancer Res Treat. 2022 Jan 12. doi: 10.1007/s10549-022-06517-3. Epub ahead of print.
    • Mutation landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and its relationship with Clinicopathological Characteristics.
    • Qianlan Y, Liu Y, Zhang L, Bao L, Bai Q, Cui Q, Xu J, Li M, Liu J, Chuai S, Ying J, Zhang Z, Zhou X.
    • Front Oncol. 2022 Jan 12;10:709645. doi: 10.3389/fonc.2022.709645.
    • Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
    • Macquere P, Orazio S, Bonnet F, Jones N, Bubien V, Chiron J, Lafon D, Barouk-Simonet E, Tinat J, Venat-Bouvet L, Gesta P, Longy M, Sevenet N.
    • J Hum Genet. 2022 Jan 12. doi: 10.1038/s10038-022-01014-3. Epub ahead of print.
    • Harnessing Synthetic Lethal Interactions for Personalized Medicine.
    • Shieh GS.
    • J Pers Med. 2022 Jan 12;12(1):98. doi: 10.3390/jpm12010098.
    • Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE, Eiriksson L.
    • Int J Gynecol Cancer. 2022 Jan 10:ijgc-2021-003082. doi: 10.1136/ijgc-2021-003082. Epub ahead of print.
    • Poly-ADP-Ribose-Polymerase(PARP)-Inhibitoren als genetisch basierte Präzisionstherapie beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) [Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].
    • Heidegger I, Becker C, Tsaur I, Todenhöfer T; Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie.
    • Urologe A. 2022 Jan 10. German. doi: 10.1007/s00120-021-01754-8. Epub ahead of print.
    • Review. [Article in German]
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2021 Nov 27:S1558-7673(21)00220-2. doi: 10.1016/j.clgc.2021.11.009. Epub ahead of print.